In conclusion, the available evidence suggests that proteins involved in the intrinsic apoptosis pathway, particularly those in the BCL-2 superfamily, play a crucial role in the development of both AML and ALL, justifying their use as therapeutic targets [43]. This evidence concerns the gene BCL2 and acute myeloid leukemia.